Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful vigilantly but unsuccessfully to produce an one off therapy, variously named Pro 140, leronlimab, and Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale of the past few shares of mine. The 1st CytoDyn post of mine, “CytoDyn: What In order to Do When It is Too Good to be able to Be True?”, set out all of the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely marketing picture in the Uptick Newswire job interview which I came away with a bad opinion of the company.

Irony of irony, my poor viewpoint of the company has grown steadily, although the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 huge number of transfers ownership of this know-how and connected intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) and also the first brand new drug application approval ($five million), and also royalty payments of 5 percent of net sales upon commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and many therapies, it has this single treatments in addition to a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy of dozens of indications.

Its opening banner on the website of its (below) shows an active company with diverse interests albeit centered on leronlimab, several disease sorts, multiple delivering presentations and multiple publications.

Might all of it be smoke cigarettes and mirrors? That’s a question I’ve been asking myself with the very start of the interest of mine in this business. Judging with the multiples of thousands of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or perhaps some may say cult stock. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *